Sugi Predict

Sugi Predict / Compounds / SCHEMBL20135490

SCHEMBL20135490

SCHEMBL20135490

Cc1cnc(N2CCN(C(=O)c3ccc(C4(C(F)(F)F)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ HTT P42858 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPK1 P28482 1/20 0.37
▸ ADAMTS5 Q9UNA0 4/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ BCR P11274 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ ADAM17 P78536 1/20 0.36
▸ SLC6A7 Q99884 1/20 0.36
▸ SLC6A9 P48067 1/20 0.36
▸ SLC6A5 Q9Y345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135515 0.92 ALDH1A1 (0.40) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL29688956 0.92 ALDH1A1 (0.40) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20135258 0.89 MEN1 (0.36) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20135021 0.89 ALDH1A1 (0.38) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20135076 0.86 ADAM17 (0.37) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20135008 0.86 ALDH1A1 (0.36) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL29688860 0.86 ALDH1A1 (0.36) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20134935 0.86 ALDH1A1 (0.42) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20134932 0.86 ALDH1A1 (0.42) MEN1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL20135327 0.85 ADAMTS5 (0.47) ADAMTS5ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885CYP1A2 491/4885CYP2C9 139/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885CYP1A2 409/4885CYP2C9 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.